Skip to main content
Log in

Accelerating the Availability of Medications to Pediatric Patients by Optimizing the Use of Extrapolation of Efficacy

Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Cite this article


Improving pediatric therapeutic development is a mission of universal importance among health authorities, pharmaceutical companies, academic institutions, and healthcare professionals. Following the passage of legislation in the United States and Europe, we witnessed the most significant advancement yet in pediatric data generation, resulting in added pediatric use information to almost 700 product labels. Tools to accelerate generation of data for the pediatric population are available for use today, and when utilized in accordance with current practices and laws, these tools could increase the amount and timeliness of pediatric information available for clinicians and patients. If we utilize the current laws that allow regulators to incentivize and require evidence generation, apply extrapolation, and utilize modeling and simulation, as well as including adolescents in the pivotal studies alongside adults as appropriate, two strategic goals could be achieved by 2030: (1) reduce the time to pediatric approval by 50%, and (2) renew pediatric labeling information for 15 priority pediatric drugs without patent and/or exclusivity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others


  1. Ward RM, Benjamin DK, Davis JM, et al. The need for pediatric drug development. J Pediatr. 2018;192:13–21.

    Article  PubMed  Google Scholar 

  2. Burckart GJ, Kim C. The revolution in pediatric drug development and drug use: therapeutic orphans no more. J Pediatr Pharmacol Ther. 2020;25:565–73.

    PubMed  PubMed Central  Google Scholar 

  3. 21 CFR 201.57 1979 (USA).

  4. 21 CFR 201 1994 (USA)

  5. FDA Modernization Act 1997 (USA)

  6. Best Pharmaceuticals for Children Act 2002 (USA)

  7. Pediatric Research Equity Act 2003 (USA)

  8. FDA Authorization Act 2007 (USA)

  9. FDA Safety and Innovation Act 2012 (USA)

  10. FDA Reauthorization Act 2017 (USA)

  11. Penkov D, Tomasi P, Eichler I, et al. Pediatric medicine development: an overview and comparison of regulatory processes in the European Union and United States. Ther Innov Regul Sci. 2017;51:360–71.

    Article  PubMed  PubMed Central  Google Scholar 

  12. US FDA. General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products.

  13. US FDA. Considerations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials, Guidance for Industry, 2019.

  14. FDA label. ZOSYN (piperacillin and tazobactam) for injection.

  15. Tornøe CW, Tworzyanski JJ, Imoisili MA, et al. Optimising piperacillin/tazobactam dosing in paediatrics. Int J Antimicrob Agents. 2007;30:320–4.

    Article  PubMed  Google Scholar 

  16. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:133–64.

    Article  PubMed  Google Scholar 

  17. US FDA, General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products: Guidance of Industry, 2014.

  18. FDA label. BETAPACE (sotalol hydrochloride) tablets, for oral use.

  19. US FDA. Approval package for: application number 19-865/S-010; Betapace(Sotalol)

  20. Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015;132:2037–99.

    Article  PubMed  Google Scholar 

  21. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Vasodilator Therapy for Primary Pulmonary Hypertension in Children.

  23. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76–81.

    Article  CAS  PubMed  Google Scholar 

  24. Douwes JM, Humpl T, Bonnet D, et al. Acute vasodilator response in pediatric pulmonary arterial hypertension: current clinical practice from the TOPP Registry. J Am Coll Cardiol. 2016;67:1312–23.

    Article  PubMed  Google Scholar 

  25. Sun H, Stockbridge N, Ariagno R, et al. Reliable and developmentally appropriate study end points are needed to achieve drug development for treatment of pediatric pulmonary arterial hypertension. J Perinatol. 2016;36:1029–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Ollivier C, Sun H, Amchin W, et al. New strategies for the conduct of clinical trials in pediatric pulmonary arterial hypertension: outcome of a multistakeholder meeting with patients, academia, industry, and regulators, held at the European Medicines Agency on Monday, June 12, 2017. J Am Heart Assoc. 2019;8: e011306.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Rapoport JL, Gogtay N. Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder. Int J Dev Neurosci. 2011;29:251–8.

    Article  PubMed  Google Scholar 

  28. Murray CJL, Lopez AD. The global burden of disease. Geneva: World Health Organization; 1996.

    Google Scholar 

  29. Vyas NS, Patel NH, Puri BK. Neurobiology and phenotypic expression in early onset schizophrenia. Early Interv Psychiatry. 2011;5:3–14.

    Article  PubMed  Google Scholar 

  30. Russell AT. The clinical presentation of childhood-onset schizophrenia. Schizophr Bull. 1994;20:631–46.

    Article  CAS  PubMed  Google Scholar 

  31. Gordon CT, Frazier JA, McKenna K, et al. Childhood-onset schizophrenia: an NIMH study in progress. Schizophr Bull. 1994;20:697–712.

    Article  CAS  PubMed  Google Scholar 

  32. Remschmidt HE, Schulz E, Martin M, et al. Childhood-onset schizophrenia: history of the concept and recent studies. Schizophr Bull. 1994;20:727–45.

    Article  CAS  PubMed  Google Scholar 

  33. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry. 2004;55:1013–22.

    Article  CAS  PubMed  Google Scholar 

  34. Russell AT, Bott L, Sammons C. The phenomenology of schizophrenia occurring in childhood. J Am Acad Child Adolesc Psychiatry. 1989;28:399–407.

    Article  CAS  PubMed  Google Scholar 

  35. Kalaria SN, Farchione TR, Mathis MV, et al. Assessment of similarity in antipsychotic exposure-response relationships in clinical trials between adults and adolescents with acute exacerbation of schizophrenia. J Clin Pharmacol. 2020;60:848–59.

    Article  CAS  PubMed  Google Scholar 

  36. Sarmast ST, Abdullahi AM, Jahan N. Current classification of seizures and epilepsies scope, limitations and recommendations for future action. Cureus. 2020;12:e10549.

    PubMed  PubMed Central  Google Scholar 

  37. Berg AT, Shinnar S, Levy SR, et al. Newly diagnosed epilepsy in children: presentation at diagnosis. Epilepsia. 1999;40:445–52.

    Article  CAS  PubMed  Google Scholar 

  38. FDA Conducts Analysis to Assess Acceptability of Extrapolation of Antiepileptic Drug (AED) Effectiveness in Adults to Children Four Years of Age and Older with Partial Onset Seizures (POS).

  39. US FDA. Drugs for Treatment of Partial Onset Seizures: Full Extrapolation of Efficacy from Adults to Pediatric Patients 2 Years of Age and Older Guidance for Industry.

  40. Spielberg DR, Clancy JP. Cystic fibrosis and its management through established and emerging therapies. Annu Rev Genomics Hum Genet. 2016;17:155–75.

    Article  CAS  PubMed  Google Scholar 

  41. Cystic Fibrosis. NHLBI, NIH.

  42. Borowitz D, Robinson KA, Rosenfeld M, et al. Cystic fibrosis foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr. 2009;155:S73-93.

    Article  PubMed  PubMed Central  Google Scholar 

  43. European Medicines Agency. Symkevi (2018)

  44. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378:169–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol. 2018;18:27.

    Article  PubMed  PubMed Central  Google Scholar 

  46. European Medicines Agency. Aubagio (2018)

  47. Green DJ, Zineh I, Burckart GJ. Pediatric drug development: outlook for science-based innovation. Clin Pharmacol Ther. 2018;103:376–8.

    Article  PubMed  Google Scholar 

  48. Hoon D, Taylor M, Kapadia P, et al. Trends in off-label drug use in ambulatory settings: 2006–2015. Pediatrics. 2019;144: e20190896.

    Article  PubMed  Google Scholar 

  49. Tanaudommongkon I, John Miyagi S, Green DJ, et al. Combined pediatric and adult trials submitted to the US Food and Drug Administration 2012–2018. Clin Pharmacol Ther. 2020;108:1018–25.

    Article  PubMed  Google Scholar 

  50. Kluetz PG, Keegan P, Demetri GD, et al. FDA Oncology Center of Excellence Project Renewal: engaging the Oncology Community to update product labeling for older oncology drugs. Clin Cancer Res. 2021;27:916–21.

    Article  CAS  PubMed  Google Scholar 

  51. Agthe AG, Kim GR, Mathias KB, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized. Controlled Trial Pediatrics. 2009;123:e849–56.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations



All authors participated in the conception and viewpoint of the manuscript. DJ conducted the Vivpro RIA analysis. AD, JG, and DJ drafted the manuscript and LB, BS, and MK provided critical revisions. All authors contributed to the final version of the manuscript.

Corresponding author

Correspondence to Jogarao V. S. Gobburu.

Ethics declarations

Conflict of interest

Dr. Jogarao V.S. Gobburu is a co-founder of Vivpro Corp and Pumas-AI.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dunn, A., Jung, D., Bollinger, L.L. et al. Accelerating the Availability of Medications to Pediatric Patients by Optimizing the Use of Extrapolation of Efficacy. Ther Innov Regul Sci 56, 873–882 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: